Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction Ignis obtains rights to develop and commercialize NeuroSigma’s FDA-approved Monarch eTNS System in ChinaInitial launch of Generation 1.0 device followed by Generation 1.5 device, to deploy in mainland...